Redeye expects to make mixed near-term estimate changes based on GomSpace's guidance announced this ...
* Q4 results due on Thursday, 5 February * Estimates up 2-4% organically, but neutralised by FX * Ma...
Redeye was surprised by Enviro’s press release on Friday evening announcing that Fredrik Emilson is ...
NextCell yesterday announced six-year follow-up data for ProTrans in type 1 diabetes, confirming tha...
OXE Marine published preliminary sales figures for Q4 which were significantly lower than we expecte...
Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 Januar...
Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financ...
The public release of Xspray’s CRL on openFDA yesterday triggered a double-digit intraday decline in...
Redeye presents a preview of Enea’s Q4 2025 report, due on 30 January 2026.
* Q4e: 4% organic sales growth, 11% adj. EBITA margin * We cut estimates on the downgraded outlook *...
Duell's Q1 figures fell short of our estimates, particularly on the top line, with sales weaker than...
* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0...
Alcadon announced this morning that it will discontinue its German operations, which comes as no maj...
Duell’s sales clearly declined in Q1 (September-November), as winter weather was weak in the Nordics...
Kalqyl och FairValue presenterar nu en samlad genomgång av sex bolag i tidig tillväxtfas, noterade p...
Redeye retains its positive view of Addnode in this Q4 Preview.
Duell reported Q1 net sales at EUR 25.0m, below our forecast of EUR 27.
Redeye comments on BONESUPPORT's announced preliminary Q4 2025 sales and sales growth target for 202...
Redeye provides a quick comment on the trading update from Cheffelo, released this morning.
